RO 318220

Drug Profile

RO 318220

Latest Information Update: 27 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Nonindustrial source; Roche
  • Class Antiasthmatics; Antihyperlipidaemics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma; Atherosclerosis; Brain cancer; Coronary artery restenosis; Transplant rejection

Most Recent Events

  • 21 Jan 1999 A preclinical study has been added to the Cancer pharmacodynamics section
  • 21 Dec 1998 Preclinical development for Brain cancer in USA (Unknown route)
  • 06 Aug 1998 No-Development-Reported for Transplant rejection in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top